Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

LXR Activation Induces a Proinflammatory Trained Innate Immunity-Phenotype in Human Monocytes.

Sohrabi Y, Sonntag GVH, Braun LC, Lagache SMM, Liebmann M, Klotz L, Godfrey R, Kahles F, Waltenberger J, Findeisen HM.

Front Immunol. 2020 Mar 10;11:353. doi: 10.3389/fimmu.2020.00353. eCollection 2020.

2.

Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study.

Heitmann H, Haller B, Tiemann L, Mühlau M, Berthele A, Tölle TR, Salmen A, Ambrosius B, Bayas A, Asseyer S, Hartung HP, Heesen C, Stangel M, Wildemann B, Haars S, Groppa S, Luessi F, Kümpfel T, Nischwitz S, Meuth SG, Klotz L, Linker RA, Zettl UK, Ziemann U, Tumani H, Tackenberg B, Zipp F, Wiendl H, Gold R, Hemmer B, Ploner M.

Pain. 2020 Apr;161(4):787-796. doi: 10.1097/j.pain.0000000000001767.

PMID:
32197038
3.

Next-Generation Neuroimmunology: New Technologies to Understand Central Nervous System Autoimmunity.

Meyer Zu Hörste G, Gross CC, Klotz L, Schwab N, Wiendl H.

Trends Immunol. 2020 Mar 5. pii: S1471-4906(20)30025-9. doi: 10.1016/j.it.2020.02.005. [Epub ahead of print] Review.

4.

Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis.

Heming M, Lohmann L, Schulte-Mecklenbeck A, Brix T, Gross CC, Wiendl H, Klotz L, Meyer Zu Hörste G.

J Neuroimmunol. 2020 Apr 15;341:577171. doi: 10.1016/j.jneuroim.2020.577171. Epub 2020 Jan 27.

5.

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab.

Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Cornelissen C, Ettle B; PANGAEA Study Group.

Mult Scler Relat Disord. 2019 Dec 13;39:101893. doi: 10.1016/j.msard.2019.101893. [Epub ahead of print]

6.

CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome.

Gross CC, Meyer C, Bhatia U, Yshii L, Kleffner I, Bauer J, Tröscher AR, Schulte-Mecklenbeck A, Herich S, Schneider-Hohendorf T, Plate H, Kuhlmann T, Schwaninger M, Brück W, Pawlitzki M, Laplaud DA, Loussouarn D, Parratt J, Barnett M, Buckland ME, Hardy TA, Reddel SW, Ringelstein M, Dörr J, Wildemann B, Kraemer M, Lassmann H, Höftberger R, Beltrán E, Dornmair K, Schwab N, Klotz L, Meuth SG, Martin-Blondel G, Wiendl H, Liblau R.

Nat Commun. 2019 Dec 18;10(1):5779. doi: 10.1038/s41467-019-13593-5.

7.

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.

Möhn N, Pfeuffer S, Ruck T, Gross CC, Skripuletz T, Klotz L, Wiendl H, Stangel M, Meuth SG.

Neurol Neuroimmunol Neuroinflamm. 2019 Dec 11;7(2). pii: e654. doi: 10.1212/NXI.0000000000000654. Print 2020 Mar.

8.

Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders.

Ringelstein M, Harmel J, Zimmermann H, Brandt AU, Paul F, Haarmann A, Buttmann M, Hümmert MW, Trebst C, Schroeder C, Ayzenberg I, Kleiter I, Hellwig K, Havla J, Kümpfel T, Jarius S, Wildemann B, Rommer P, Weber MS, Pellkofer H, Röpke L, Geis C, Retzlaff N, Zettl U, Deppe M, Klotz L, Young K, Stellmann JP, Kaste M, Kermer P, Marouf W, Lauda F, Tumani H, Graf J, Klistorner A, Hartung HP, Aktas O, Albrecht P; Neuromyelitis Optica Study Group (NEMOS).

Neurology. 2020 Jan 28;94(4):e407-e418. doi: 10.1212/WNL.0000000000008684. Epub 2019 Dec 3.

PMID:
31796527
9.

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.

Keller CW, Ruck T, McHugh D, Pfeuffer S, Gross CC, Korsukewitz C, Melzer N, Klotz L, Meuth SG, Münz C, Nimmerjahn F, Wiendl H, Lünemann JD.

Ann Clin Transl Neurol. 2019 Dec;6(12):2586-2594. doi: 10.1002/acn3.50935. Epub 2019 Nov 4.

10.

Sub-Inhibitory concentrations of SOS-Response inducing antibiotics stimulate integrase expression and excision of pathogenicity islands in uropathogenic Escherichia coli strain 536.

Chittò M, Berger M, Klotz L, Dobrindt U.

Int J Med Microbiol. 2020 Jan;310(1):151361. doi: 10.1016/j.ijmm.2019.151361. Epub 2019 Oct 7.

PMID:
31640923
11.

EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases.

von Martial S, Brix TJ, Klotz L, Neuhaus P, Berger K, Warnke C, Meuth SG, Wiendl H, Dugas M.

PLoS One. 2019 Oct 15;14(10):e0223886. doi: 10.1371/journal.pone.0223886. eCollection 2019.

12.

Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis.

Herich S, Schneider-Hohendorf T, Rohlmann A, Khaleghi Ghadiri M, Schulte-Mecklenbeck A, Zondler L, Janoschka C, Ostkamp P, Richter J, Breuer J, Dimitrov S, Rammensee HG, Grauer OM, Klotz L, Gross CC, Stummer W, Missler M, Zarbock A, Vestweber D, Wiendl H, Schwab N.

Brain. 2019 Nov 1;142(11):3411-3427. doi: 10.1093/brain/awz301.

PMID:
31563951
13.

Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.

Schwab N, Schneider-Hohendorf T, Pignolet B, Bucciarelli F, Scandella L, Ciron J, Biotti D, Lebrun-Frenay C, Mathey G, Clavelou P, Pelletier J, Ostkamp P, Meinl I, Windhagen S, Klotz L, Gross CC, Meuth SG, Deisenhammer F, Brassat D, Wiendl H; Best-MS Study Group.

Neurology. 2019 Sep 17;93(12):550-554. doi: 10.1212/WNL.0000000000008135. Epub 2019 Aug 22. No abstract available.

PMID:
31439633
14.

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study.

Ruck T, Schulte-Mecklenbeck A, Pfeuffer S, Heming M, Klotz L, Windhagen S, Kleinschnitz C, Gross CC, Wiendl H, Meuth SG.

EBioMedicine. 2019 Aug;46:381-386. doi: 10.1016/j.ebiom.2019.07.062. Epub 2019 Jul 29.

15.

Social Defeat Modulates T Helper Cell Percentages in Stress Susceptible and Resilient Mice.

Ambrée O, Ruland C, Zwanzger P, Klotz L, Baune BT, Arolt V, Scheu S, Alferink J.

Int J Mol Sci. 2019 Jul 17;20(14). pii: E3512. doi: 10.3390/ijms20143512.

16.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Dec;90(12):1245-1253. doi: 10.1007/s00115-019-0760-0. Review. German.

PMID:
31297574
17.

Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.

Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, Torres Garrido B, Schulte-Mecklenbeck A, Gross CC, Breuer J, Hundehege P, Posevitz V, Pignolet B, Nebel G, Glander S, Freise N, Austermann J, Wirth T, Campbell GR, Schneider-Hohendorf T, Eveslage M, Brassat D, Schwab N, Loser K, Roth J, Busch KB, Stoll M, Mahad DJ, Meuth SG, Turner T, Bar-Or A, Wiendl H.

Sci Transl Med. 2019 May 1;11(490). pii: eaao5563. doi: 10.1126/scitranslmed.aao5563.

PMID:
31043571
18.

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies.

Heming M, Schulte-Mecklenbeck A, Brix T, Wolbert J, Ruland T, Klotz L, Meuth SG, Gross CC, Wiendl H, Meyer Zu Hörste G.

Front Immunol. 2019 Mar 21;10:515. doi: 10.3389/fimmu.2019.00515. eCollection 2019.

19.

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.

Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H.

Ther Adv Neurol Disord. 2019 Apr 1;12:1756286419836571. doi: 10.1177/1756286419836571. eCollection 2019. Review.

20.

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.

Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Couto CA, Findlay JA, Cornelissen C; PANGAEA study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e548. doi: 10.1212/NXI.0000000000000548. eCollection 2019 May.

Supplemental Content

Loading ...
Support Center